Aquamarine Financial (Cayman) Ltd 13F: Quarter-over-Quarter Portfolio Changes
Aquamarine Financial (Cayman) Ltd reported a disclosed portfolio value of approximately $1.4 billion in its latest SEC Form 13F-HR filing for Q1 2026, up 11.2% quarter on quarter. Over the quarter, the fund initiated 4 new positions, bought more shares in 6 holdings, and trimmed 3 holdings.
Aquamarine Financial (Cayman) Ltd's top buy was a new stake in Proshares Tr II (SCOUSD) , equal to 2.1% of the disclosed portfolio. Its top sell was Gerdau SA (GGB) . The fund sold 14.3% of its previously reported shares, reducing the position's portfolio weight by 1.4 percentage points.
New PositionsQ1 2026
Securities disclosed for the first time in Q1 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| PROSHARES TR II | SCOUSD | 2.1% | History → |
| NU HOLDINGS LTD | NU | 1.1% | History → |
| ALPHA TAU MEDICAL LTD | DRTS | 0.4% | Holders → |
| PULSENMORE LTD | PLSM | 0.1% | Holders → |
Top BuysQ1 2026
The fund's top buys among existing positions in Q1 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| INNOVIZ TECHNOLOGIES LTD | INVZ | +0.2% | +2820.4% | Holders → |
| GRUPO FINANCIERO GALICIA S.A | GGAL | +-1.1% | +12.8% | History → |
| BBVA ARGENT-ADR | BBAR | +-0.2% | +8.2% | History → |
| ORAMED PHARMACEUTICALS INC | ORMP | +0.1% | +7.1% | Holders → |
| BANCO BRADESCO S A | BBD | +1.0% | +5.5% | History → |
| BANCO SANTANDER BRASIL S A | BSBR | +-0.6% | +0.5% | History → |
Top SellsQ1 2026
The fund's top sells among positions it retained in Q1 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| GERDAU SA | GGB | -1.4% | 14.3% | History → |
| YPF SA-ADR | YPF | -0.3% | 14.0% | History → |
| BANCO MACRO SA | BMA | -1.1% | 5.7% | History → |
Net Portfolio Value ChangeQ1 2026
- $1.2BPrior quarter
- $1.4BCurrent quarter
- +$0.1BNet delta
- +11.2%% change
Methodology & FAQ
How Aquamarine Financial (Cayman) Ltd Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Aquamarine Financial (Cayman) Ltd: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description — including how confidential treatment filings are handled — is documented in the Methodology.
What stocks did Aquamarine Financial (Cayman) Ltd buy in Q1 2026?
In Q1 2026, Aquamarine Financial (Cayman) Ltd initiated 4 new positions (PROSHARES TR II (SCOUSD), NU HOLDINGS LTD (NU), ALPHA TAU MEDICAL LTD (DRTS), PULSENMORE LTD (PLSM)); bought more shares of INNOVIZ TECHNOLOGIES LTD (INVZ), GRUPO FINANCIERO GALICIA S.A (GGAL), BBVA ARGENT-ADR (BBAR), ORAMED PHARMACEUTICALS INC (ORMP), BANCO BRADESCO S A (BBD) — the largest 5 of 6 adds.
What stocks did Aquamarine Financial (Cayman) Ltd sell in Q1 2026?
In Q1 2026, Aquamarine Financial (Cayman) Ltd reduced holdings in GERDAU SA (GGB), YPF SA-ADR (YPF), BANCO MACRO SA (BMA).
Which positions did Aquamarine Financial (Cayman) Ltd initiate in Q1 2026?
Aquamarine Financial (Cayman) Ltd established 4 new positions in Q1 2026: PROSHARES TR II (SCOUSD, 2.1%), NU HOLDINGS LTD (NU, 1.1%), ALPHA TAU MEDICAL LTD (DRTS, 0.4%), PULSENMORE LTD (PLSM, 0.1%).
Which existing positions saw the largest allocation increases for Aquamarine Financial (Cayman) Ltd in Q1 2026?
Of 6 existing positions with share-count increases in Q1 2026, the largest were: INNOVIZ TECHNOLOGIES LTD (INVZ, +0.2% weight, +2820.4% shares), GRUPO FINANCIERO GALICIA S.A (GGAL, +-1.1% weight, +12.8% shares), BBVA ARGENT-ADR (BBAR, +-0.2% weight, +8.2% shares), ORAMED PHARMACEUTICALS INC (ORMP, +0.1% weight, +7.1% shares), BANCO BRADESCO S A (BBD, +1.0% weight, +5.5% shares), BANCO SANTANDER BRASIL S A (BSBR, +-0.6% weight, +0.5% shares).
Which positions did Aquamarine Financial (Cayman) Ltd fully exit in Q1 2026?
Aquamarine Financial (Cayman) Ltd fully exited no positions in Q1 2026.
Which existing positions saw the largest allocation reductions for Aquamarine Financial (Cayman) Ltd in Q1 2026?
Of 3 existing positions with share-count reductions in Q1 2026, the largest were: GERDAU SA (GGB, -1.4% weight, -14.3% shares), YPF SA-ADR (YPF, -0.3% weight, -14.0% shares), BANCO MACRO SA (BMA, -1.1% weight, -5.7% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.